Siga Technologies (SIGA) Cash & Equivalents (2010 - 2025)
Siga Technologies' (SIGA) quarterly Cash & Equivalents came in at $155.0 million in Q4 2025, little changed on a YoY basis from $155.4 million in Q4 2024, and down 9.88% quarter-over-quarter from $172.0 million in Q3 2025.
Analysis
Siga Technologies (SIGA) Cash & Equivalents (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Cash & Equivalents for 16 consecutive years, with $155.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents changed 0.28% year-over-year to $155.0 million; the trailing twelve-month figure through Dec 2025 stood at $155.0 million (changed 0.28% YoY), and the FY2025 full-year result was $155.0 million, changed 0.28% from the prior year.
- Cash & Equivalents slipped to $155.0 million in Q4 2025 per SIGA's latest filing, from $172.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $182.5 million in Q2 2025 and bottomed at $71.1 million in Q3 2023.
- Historically, Cash & Equivalents has averaged $123.4 million across 5 years, with a median of $112.1 million in 2022.
- The sharpest annual moves came in 2021 and 2023: Cash & Equivalents jumped 85.59% in 2021, then plunged 35.2% in 2023.
- Over 5 years, Cash & Equivalents stood at $103.1 million in 2021, then declined by 4.22% to $98.8 million in 2022, then soared by 51.98% to $150.1 million in 2023, then increased by 3.5% to $155.4 million in 2024, then retreated by 0.28% to $155.0 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $155.0 million, $172.0 million, and $182.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 976.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 815.44 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 3.98 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 1.80 Bn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - | 154.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 154.97 Mn |
| Sep 30, 2025 | 171.96 Mn |
| Jun 30, 2025 | 182.46 Mn |
| Mar 31, 2025 | 162.27 Mn |
| Dec 31, 2024 | 155.40 Mn |
| Sep 30, 2024 | 99.27 Mn |
| Jun 30, 2024 | 106.95 Mn |
| Mar 31, 2024 | 143.87 Mn |
| Dec 31, 2023 | 150.15 Mn |
| Sep 30, 2023 | 71.11 Mn |
| Jun 30, 2023 | 76.21 Mn |
| Mar 31, 2023 | 115.68 Mn |
| Dec 31, 2022 | 98.79 Mn |
| Sep 30, 2022 | 109.75 Mn |
| Jun 30, 2022 | 114.53 Mn |
| Mar 31, 2022 | 153.26 Mn |
| Dec 31, 2021 | 103.14 Mn |
| Sep 30, 2021 | 92.82 Mn |
| Jun 30, 2021 | 98.49 Mn |
| Mar 31, 2021 | 106.53 Mn |